The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 701–800 of 1,056
Inflammatory cells and chemokines sustain FGF2-induced angiogenesis
Presta, M., Andrés, G., Leali, D., Dell'Era, P., & Ronca, R. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0155 · Cited by 156
“Then, the VEGF family of angiogenic growth factors came into the limelight after the discovery of their pivotal role in vasculogenesis and angiogenesis during embryonic development and under numerous physiological and pathological conditions in adults [33].”
BackgroundAngiogenesis and Fibrogenesis in Chronic Liver Diseases
Bocca, C., Novo, E., Miglietta, A., & Parola, M. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.06.011 · Cited by 151
Leelahavanichkul, A., Huang, Y., Hu, X., Zhou, H., Tsuji, T., Chen, R., Kopp, J. B., Schnermann, J., Yuen, P. S. T., & Star, R. A. (2011) · Kidney International · doi:10.1038/ki.2011.261 · Cited by 158
“Soluble fms-like tyrosine kinase 1 (sFLT-1) is an endogenous, circulating VEGF receptor splice variant that can serve as a VEGF antagonist.(41) We attempted to counteract the decreased clearance of VEGF”
BackgroundCheng, W., Feng, Y., Ding, L., Ju, H., & Yin, Y. (2010) · Analytical Chemistry · doi:10.1021/ac100144g · Cited by 158
Hou, J. C.-T., Kshettry, V. R., Selman, W. R., & Bambakidis, N. C. (2013) · Neurosurgical FOCUS · doi:10.3171/2013.8.focus13301 · Cited by 158
“25 Vascular endothelial growth factor-A is an important member of a family of signaling molecules including VEGF-B, VEGF-C, and VEGF-D, expressed by a number of cells, such as meningioma stromal and endothelial cells in the presence of hypoxia.”
BackgroundO’Connor, J. P. B., Carano, R. A. D., Clamp, A. R., Ross, J., Ho, C., Jackson, A., Parker, G. J. M., Rose, C. J., Peale, F. V., Jr., Friesenhahn, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0731 · Cited by 167
“Consequently, VEGF signaling has become an important target in drug development and has led to Food and Drug Administration approval of drugs that target either VEGF or the VEGF receptor (3, 4).”
BackgroundSelf-citationChang, Y. S., Jalgaonkar, S. P., Middleton, J. D., & Hai, T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700455114 · Cited by 157
“Because VEGFA is highly proangiogenic (72), the tumor microenvironment may already be saturated with angiogenic signals, making it difficult to detect the effect of PTX in increasing vessel density.”
BackgroundHuman mast cells and basophils—How are they similar how are they different?
Varricchi, G., Raap, U., Rivellese, F., Marone, G., & Gibbs, B. F. (2018) · Immunological Reviews · doi:10.1111/imr.12627 · Cited by 151
Angiogenesis in the ischemic core: A potential treatment target?
Kanazawa, M., Takahashi, T., Ishikawa, M., Onodera, O., Shimohata, T., & del Zoppo, G. J. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19834158 · Cited by 163
Wang, L., Wakisaka, N., Tomlinson, C. C., DeWire, S. M., Krall, S. P., Pagano, J. S., & Damania, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3653 · Cited by 172
“VEGF is overexpressed in many tumor cells, and elevated VEGF levels are associated with tumor metastasis (76).”
BackgroundSynthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome
Negussie, A. H., Miller, J. L., Reddy, G., Drake, S. K., Wood, B. J., & Dreher, M. R. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.031 · Cited by 156
“Widely used tumor vascular targets include integrins [10,11], vascular endothelial growth factor receptor (VEGFR) [12,13], platelet-derived growth factor receptor (PDGFR) [14,15], and CD13/aminopeptidase N (APN, referred to as CD13 throughout) [2,16–21].”
Overcoming key biological barriers to cancer drug delivery and efficacy
Kim, S. M., Faix, P. H., & Schnitzer, J. E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.016 · Cited by 151
“Heterogeneity in tumor vasculature may be a major factor contributing to the disappointing clinical performances of contemporary anti-angiogenic drugs that are typically designed to block tumor angiogenesis by inhibiting VEGF, specific VEGF receptors or key downstream targets in VEGF receptor signaling pathways [56,57…”
BackgroundSiebert, L., Ceron, E. L., García‐Rivera, L. E., Oh, J.-S., Jang, J., Rosas‐Gómez, D. A., Pérez‐Gómez, M. D., Maschkowitz, G., Fickenscher, H., Oceguera‐Cuevas, D., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202007555 · Cited by 170
VEGF-A165 augments erythropoietic development from human embryonic stem cells
Cerdan, C., Rouleau, A., & Bhatia, M. (2003) · Blood · doi:10.1182/blood-2003-07-2563 · Cited by 168
Zolla, V., Nizamutdinova, I. T., Scharf, B., Clement, C. C., Maejima, D., Akl, T., Nagai, T., Luciani, P., Leroux, J., Halin, C., et al. (2015) · Aging Cell · doi:10.1111/acel.12330 · Cited by 148
“5m) (Ferrara et al., 2003).”
Key cancer cell signal transduction pathways as therapeutic targets
Bianco, R., Melisi, D., Ciardiello, F., & Tortora, G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.034 · Cited by 179
Axitinib for the Management of Metastatic Renal Cell Carcinoma
Escudier, B., & Gore, M. (2011) · Drugs in R & D · doi:10.1007/bf03259801 · Cited by 153
“VEGFR-1 is involved in angiogenesis and tumor growth; VEGFR-2 is involved in endothelial cell proliferation, migration and survival, and angiogenesis; and VEGFR-3 is involved in lymphangiogenesis.([28,30])”
BackgroundSu, M., Lin, S., & Chen, Y. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmr027 · Cited by 155
“Vascular endothelial growth factor (VEGF) is a potent angiogenic factor and a survival factor for endothelial cells during physiological and tumor angiogenesis, and functions in vasodilatation, vascular permeability and anti-apoptosis (Benjamin and Keshet, 1997; Ferrara et al., 2003).”
BackgroundEngineered delivery strategies for enhanced control of growth factor activities in wound healing
Niu, Y., Li, Q., Ding, Y., Dong, L., & Wang, C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.002 · Cited by 162
Nakatsu, M. N., Sainson, R. C. A., Pérez‐del‐Pulgar, S., Aoto, J. N., Aitkenhead, M., Taylor, K. L., Carpenter, P. M., & Hughes, C. C. W. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000107160.81875.33 · Cited by 169
“Previous reports have suggested that VEGFR-1–mediated signaling is relatively weak and that VEGFR-1 may act as a “sink” for VEGF, thereby trapping available VEGF and limiting the interaction between VEGF and VEGFR-2 (Ferrara et al, 2003; Park et al, 1994).”
BackgroundVascular endothelial growth factor: Biology and therapeutic applications
Ho, Q. T., & Kuo, C. J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.04.010 · Cited by 182
“VEGF has subsequently been implicated in a variety of functions during adult physiology including ovarian angiogenesis, endochondral bone formation, tissue regeneration, haematopoietic stem cell survival, erythropoietin regulation, and pathological processes such as neoplastic, hematologic, ocular, inflammatory, and i…”
BackgroundInfluentialUd‐Din, S., Sebastian, A., Pamela, G., Colthurst, J., Whiteside, S., Morris, J., Nuccitelli, R., Pullar, C. E., Baguneid, M. S., & Bayat, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124502 · Cited by 163
Advances in understanding the leukaemia microenvironment
Tabe, Y., & Konopleva, M. Y. (2014) · British Journal of Haematology · doi:10.1111/bjh.12725 · Cited by 172
“VEGF secreted by leukemic cells activates receptors on both leukemic and endothelial cells and plays a vital role in the growth of leukemia cells (Ferrara et al, 2003).”
BackgroundWalker, F., Abramowitz, L., Benabderrahmane, D., Duval, X., Descatoire, V., Hénin, D., Lehy, T., & Aparicio, T. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.05.010 · Cited by 154
“VEGFR1 is a particularly promising candidate because (i) it binds 3 ligands (VEGFA, VEGFB, and placenta growth factor), (ii) it is up-regulated by hypoxia, which frequently occurs in carcinoma [15], and (iii) it is a potential target for anticancer vaccines against angiogenesis [16].”
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
Roviello, G., Ravelli, A., Połom, K., Petrioli, R., Marano, L., Marrelli, D., Roviello, F., & Generali, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.014 · Cited by 159
Kim, J. H., Kim, M. H., Jo, D. H., Yu, Y. S., Lee, T. G., & Kim, J. H. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.030 · Cited by 157
αB-crystallin regulation of angiogenesis by modulation of VEGF
Kase, S., He, S., Sonoda, S., Kitamura, M., Spee, C. K., Wawrousek, E. F., Ryan, S. J., Kannan, R., & Hinton, D. R. (2009) · Blood · doi:10.1182/blood-2009-01-197095 · Cited by 170
Zuo, Y., Liu, X., Wei, D., Sun, J., Xiao, W., Zhao, H., Guo, L., Wei, Q., Fan, H., & Zhang, X. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b01433 · Cited by 153
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding
Li, M., & Kroetz, D. L. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.012 · Cited by 160
Ischemic Retinopathies: Oxidative Stress and Inflammation
Rivera, J. C., Dabouz, R., Noueihed, B., Omri, S., Tahiri, H., & Chemtob, S. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3940241 · Cited by 160
“VEGF antagonists attenuate vascular leakage in DR [99].”
BackgroundYu, W., Wang, J., & Yin, J. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2010.544432 · Cited by 166
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain
Selvaraj, D., Gangadharan, V., Michalski, C. W., Kurejová, M., Stösser, S., Srivastava, K., Schweizerhof, M., Waltenberger, J. L., Ferrara, N., Heppenstall, P. A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.017 · Cited by 163
“Intraplantar application of VEGF-E, a specific agonist at VEGFR2 (Ferrara et al., 2003) (Figure 2A), at doses up to 100 ng, did not evoke any changes in mechanical or thermal sensitivity as compared with saline injection (Figures 2F and S2B).”
BackgroundMethodResultInfluentialSelf-citationAird, S. D., Watanabe, Y., Villar‐Briones, A., Roy, M. C., Terada, K., & Mikheyev, A. S. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-790 · Cited by 158
Gelfand, M. V., Hagan, N., Tata, A., Oh, W.-J., Lacoste, B., Kang, K.-T., Kopycinska, J., Bischoff, J., Wang, J.-H., & Gu, C. (2014) · eLife · doi:10.7554/elife.03720 · Cited by 148
“…mechanisms underlying angiogenesis have become increasingly clear, and VEGF is an essential player in this process ( Carmeliet et al., 1996 , 1999 ; Ferrara et al., 1996 , 2003 ; Iruela-Arispe and Dvorak, 1997 ; Miquerol et al., 1999 ; Ruhrberg et al., 2002 ; Stalmans et al., 2002 ; Rossant and…”
BackgroundGoh, J. X. H., Tan, L. T., Goh, J. K., Chan, K., Pusparajah, P., Lee, L., & Goh, B. H. (2019) · Cancers · doi:10.3390/cancers11060867 · Cited by 155
Osusky, K. L., Hallahan, D. E., Fu, A., Ye, F., Shyr, Y., & Geng, L. (2004) · Angiogenesis · doi:10.1007/s10456-004-3149-y · Cited by 155
Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer
Ellis, L. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.002 · Cited by 172
Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer
Yamamoto, Y., Ibusuki, M., Okumura, Y., Kawasoe, T., Kai, K., Iyama, K., & Iwase, H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9742-1 · Cited by 151
“One of the most important positive regulators for breast cancer angiogenesis is VEGF [26], which is directly implicated in endothelial cell proliferation, migration, protease expression, cell adhesion, capillary tube formation, vessel maturation and vascular permeability [27].”
Association of Genetic Polymorphisms in the VEGF Gene with Breast Cancer Survival
Lu, H., Shu, X., Cui, Y., Kataoka, N., Wen, W., Cai, Q., Ruan, Z.-X., Gao, Y., & Zheng, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2786 · Cited by 151
“VEGF specifically binds to two transmembrane VEGF receptor tyrosine kinases on endothelial cells to initiate intracellular signal transduction pathways that mediate angiogenesis and vascular permeability (3).”
BackgroundLynch, A. M., & Salmon, J. E. (2010) · Placenta · doi:10.1016/j.placenta.2010.03.010 · Cited by 151
Molecular Biology of Head and Neck Cancer
Lam, D. K., & Schmidt, B. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-2527-6.00010-4 · Cited by 155
Anti-inflammation biomaterial platforms for chronic wound healing
Xu, Z., Liang, B., Tian, J., & Wu, J. (2021) · Biomaterials Science · doi:10.1039/d1bm00637a · Cited by 153
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Increased CSF biomarkers of angiogenesis in Parkinson disease
Janelidze, S., Lindqvist, D., Francardo, V., Hall, S., Zetterberg, H., Blennow, K., Adler, C. H., Beach, T. G., Serrano, G. E., van Westen, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002151 · Cited by 150
NADPH Oxidase Activity Selectively Modulates Vascular Endothelial Growth Factor Signaling Pathways
Abid, M. R., Spokes, K. C., Shih, S.-C., & Aird, W. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702175200 · Cited by 150
Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina
Dorrell, M. I., & Friedlander, M. (2006) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2006.01.001 · Cited by 171
Zhang, L., Zhou, F., Han, W., Shen, B., Luo, J., Shibuya, M., & He, Y. (2010) · Cell Research · doi:10.1038/cr.2010.116 · Cited by 152
Cancer stem cells and tumor metastasis
LI, S., & LI, Q. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2362 · Cited by 145
“Targeting VEGFR-3 may provide additional efficacy for anti-angiogenic therapies, especially towards vessels that are resistant to VEGF or VEGFR-2 inhibitors (17).”
BackgroundBianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4905 · Cited by 149
“giogenic protein (6), binds to three distinct VEGF receptors (VEGFR): VEGFR-1 (Flt-1), VEGFR-2 (KDR or the murine homologue Flk-1), and VEGFR-3 (Flt-4; ref.”
BackgroundTargeted Therapy for Breast Cancer
Mohamed, A., Krajewski, K., Çakar, B., & Ma, C. X. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.005 · Cited by 171
Badv, M., Bayat, F., Weitz, J. I., & Didar, T. F. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120291 · Cited by 152
FGF9 and SHH regulate mesenchymalVegfaexpression and development of the pulmonary capillary network
White, A. C., Lavine, K. J., & Ornitz, D. M. (2007) · Development · doi:10.1242/dev.004879 · Cited by 149
Liang, Y., Brekken, R. A., & Hyder, S. M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01221 · Cited by 148
“proliferative response in other cell types (Ferrara et al. 2003).”
BackgroundInfluentialAngiogenesis, adipokines and breast cancer
Vona-Davis, L., & Rose, D. P. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.05.007 · Cited by 148
“The molecular forms and multiple sites of action of VEGF on the angiogenesis pathway have been well reviewed [for example [5,30]] and will not be detailed here; the biological actions include the stimulation of VEC proliferation [5,30] and the Bcl-2-mediated suppression of apoptosis [31], induction of proteolytic enzy…”
BackgroundHsu, J. Y., & Wakelee, H. A. (2009) · BioDrugs · doi:10.2165/11317600-000000000-00000 · Cited by 165
“These ligands bind to a family of receptors (VEGFR), transmembrane receptor tyrosine kinases, which are involved in signaling pathways essential for vascular endothelial cell division and migration.([3]) The family member VEGF-A (also known as VEGF) is demonstrated to be important in tumor angiogenesis.”
BackgroundYe, W., Lv, Q., Wong, C.-K. A., Hu, S., Fu, C., Zhong, H., Cai, G., Li, G., Yang, B. B., & Zhang, Y. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001719 · Cited by 158
“VEGF is an important regulator of physiological or pathological angiogenesis and is involved in embryogenesis, wound healing, and tumorigenesis [41].”
BackgroundMetronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer
Kamat, A. A., Kim, T. J., Landen, C. N., Lu, C., Han, L. Y., Lin, Y. G., Merritt, W. M., Thaker, P. H., Gershenson, D. M., Bischoff, F. Z., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3282 · Cited by 162
Epidemiology, disease Progression, and Economic Burden of Colorectal Cancer
Benson, A. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.s6-c.5 · Cited by 149
Essential Roles of EphB Receptors and EphrinB Ligands in Endothelial Cell Function and Angiogenesis
(2012) · Advances in Cancer Research · doi:10.1016/b978-0-12-386503-8.00002-8 · Cited by 141
Paths of FGFR-driven tumorigenesis
Acevedo, V. D., Ittmann, M., & Spencer, D. M. (2009) · Cell Cycle · doi:10.4161/cc.8.4.7657 · Cited by 143
Zou, D., Zhang, Z., He, J., Zhang, K., Ye, D., Han, W., Zhou, J., Wang, Y., Li, Q., Liu, X., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.053 · Cited by 150
“VEGF is regarded as a key angiogenic factor that has the strongest and most significant biological activity in enhancing blood formation [29].”
BackgroundEffects of vascular endothelial growth factor in ischemic stroke
Ma, Y., Zechariah, A., Qu, Y., & Hermann, D. M. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23088 · Cited by 145
“The major function of VEGFR-1 is thought to be as a ‘‘decoy receptor’’ that negatively regulates angiogenesis by preventing the binding of VEGF to VEGFR2 (Park et al., 1993; Ferrara et al., 2003; Roskoski, 2008).”
BackgroundCarneiro, Â. M., Costa, R., Falcão, M. S., Barthelmes, D., Mendonça, L. S., Fonseca, S. L., Gonçalves, R., Gonçalves, C., Falcão‐Reis, F. M., & Soares, R. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02240.x · Cited by 147
“These results are important as VEGF is fundamental for numerous physiological extra-ocular functions, namely survival of endothelial vascular cells, neurotrophic effects and a homoeostatic factor for blood pressure and cardiovascular system (Zachary et al. 2000; Ferrara et al. 2003).”
BackgroundLin, F.-J., Chen, X., Qin, J., Hong, Y.-K., Tsai, M.-J., & Tsai, S. Y. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40101 · Cited by 143
Cheng, S., Zhang, X., Feng, Q., Chen, J., Shen, L., Yu, P., Yang, L., Chen, D., Zhang, H., Sun, W., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.040 · Cited by 147
Tumor endothelial markers: new targets for cancer therapy
Nanda, A., & Croix, B. S. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200401000-00009 · Cited by 159
Affolter, M., & Caussinus, E. (2008) · Development · doi:10.1242/dev.014498 · Cited by 139
“Members of the vascular endothelial growth factor (Vegf) family of signalling molecules are key regulators of blood vessel formation and function, and act through receptor tyrosine kinases of the Vgfr family (Ferrara et al., 2003).”
BackgroundZentilin, L., Tafuro, S., Zacchigna, S., Arsic, N., Pattarini, L., Sinigaglia, M., & Giacca, M. (2006) · Blood · doi:10.1182/blood-2005-08-3215 · Cited by 149
Mechanisms of Disease: angiogenesis and the management of breast cancer
Banerjee, S. N., Dowsett, M., Ashworth, A., & Martin, L. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0905 · Cited by 156
“The VEGF protein family consists of at least seven structurally related glycoproteins VEGFA, VEGFB, VEGFC, VEGFD, VEGFE and placenta growth factors 1 and 2”
BackgroundAntitumor Peptides from Marine Organisms
Zheng, L.-H., Wang, Y.-J., Sheng, J., Wang, F., Zheng, Y., Lin, X.-K., & Sun, M. (2011) · Marine Drugs · doi:10.3390/md9101840 · Cited by 146
“Vascular endothelial growth factor (VEGF) and its receptor, VEGFR-2 (Flk-1/KDR), play a key role in tumor angiogenesis [80,81].”
BackgroundClinical Pharmacology of Axitinib
Chen, Y., Tortorici, M. A., Garrett, M., Hee, B., Klamerus, K. J., & Pithavala, Y. K. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0068-3 · Cited by 146
“The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) signaling pathways are critical not only for normal vascular development during embryogenesis and angiogenesis later in adults, but also have been implicated in the survival, growth and metastasis of tumors [1–3].”
BackgroundA bioactive self-assembled membrane to promote angiogenesis
Chow, L. W., Bitton, R., Webber, M. J., Carvajal, D., Shull, K. R., Sharma, A. K., & Stupp, S. I. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.048 · Cited by 142
The role of the organ microenvironment in the biology and therapy of cancer metastasis
Fidler, I. J., Kim, S., & Langley, R. R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21148 · Cited by 143
“In addition, VEGF/VPF regulates endothelial cell survival by activating the phosphatidylinositol-3 kinase/Akt signal transduction pathway and stimulating expression of the antiapoptotic proteins Bcl-2 and A1 [Hicklin and Ellis, 2005].”
BackgroundInfluentialGrellier, M., Tojais, N. F., Bourget, C., Bareille, R., Guillemot, F., & Amédée, J. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22018 · Cited by 146
“VEGF is a major promoter of both physiological and pathological angiogenesis that belongs to a family of homodimeric proteins consisting of six members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor [Cross et al., 2003; Ferrara et al., 2003].”
BackgroundVEGFR-2 conformational switch in response to ligand binding
Sarabipour, S., Ballmer‐Hofer, K., & Hristova, K. A. (2016) · eLife · doi:10.7554/elife.13876 · Cited by 147
“Angiogenesis is regulated by the ligands and receptors of the vascular endothelial growth factor (VEGF) signaling network (Ferrara et al., 2003; Matsumoto et al., 2001; Koch et al., 2011; Olsson et al., 2006; Shibuya et al., 2006).”
BackgroundLazăr, D. C., Avram, M. F., Romosan, I., Cornianu, M., Tăban, S. M., & Goldiș, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i32.3583 · Cited by 168
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Duda, D. G., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.001 · Cited by 156
“In adults, VEGF acts as a potent inducer of vascular permeability and as a survival and mitogen factor for endothelial cells [6,7].”
BackgroundTintu, A., Rouwet, E., Verlohren, S., Brinkmann, J., Ahmad, S., Crispi, F., van Bilsen, M., Carmeliet, P., Staff, A. C., Tjwa, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005155 · Cited by 147
“VEGF is a hypoxia-regulated cytokine that plays a pivotal role in angiogenesis, neurogenesis, and cardiac morphogenesis [11–13].”
BackgroundThe role of angiogenesis in solid tumours: An overview
Makrilia, N., Lappa, T., Xyla, V., Nikolaidis, I., & Syrigos, K. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.07.009 · Cited by 171
“The VEGF family includes the VEGF-A, -B, -C, -D, -E factors (Tables 1 and 2) and the placenta growth factor (PIGF) [4].”
BackgroundHerbst, R. S., Heymach, J. V., O’Reilly, M. S., Onn, A., & Ryan, A. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.239 · Cited by 143
“VEGF has been identified as the most potent and specific mitogen for vascular endothelial cells and it is now widely accepted that VEGF/VEGFR signaling is a key driver of tumor angiogenesis [1].”
BackgroundGreenaway, J. B., Connor, K. L., Pedersen, H. G., Coomber, B. L., LaMarre, J., & Petrik, J. (2004) · Endocrinology · doi:10.1210/en.2003-1620 · Cited by 145
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Crawford, Y., & Ferrara, N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.004 · Cited by 156
Self-citationMetzger, G. J. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.023 · Cited by 144
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Chaskis, C., Dujardin, M., Everaert, H., Lv, S., Duerinck, J., Tynninen, O., Nupponen, N. N., Michotte, A., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0402-7 · Cited by 144
“HGG typically express a high level of vascular endothelial growth factor (VEGF) [7], a protein that is produced both by tumor cells and stromal cells, including inflammatory cells [8, 9], and that is associated with poor prognosis [ 10 ].”
BackgroundNF-κB signaling pathway in tumor microenvironment
Cao, Y., Yi, Y., Han, C., & Shi, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476030 · Cited by 164
“VEGF interacts with two primary receptor tyrosine kinases: VEGFR1 (fms-like tyrosine kinase, or Flt-1) and VEGFR2 (kinase insert domain receptor/ fetal liver kinase-1, or KDR/ fl k-1) (87).”
BackgroundMellou, F., Loutrari, H. V., Stamatis, H., Roussos, C., & Kolisis, F. N. (2006) · Process Biochemistry · doi:10.1016/j.procbio.2006.05.002 · Cited by 144
McGee, M. C., Hamner, J. B., Williams, R. F., Rosati, S. F., Sims, T. L., Ng, C. Y., Gaber, M. W., Calabrese, C., Wu, J., Nathwani, A. C., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.010 · Cited by 137
“These tumors have been shown to express increased levels of a variety of angiogenic factors, including vascular endothelial growth factor (VEGF) (5–7), a cytokine known to play a critical role in the angiogenic phenotype of these and other solid tumors (8, 9).”
Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways
Romon, R., Adriaenssens, É., Lagadec, C. H., Germain, E., Hondermarck, H., & Bourhis, X. L. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-157 · Cited by 155
“These include VEGF [34] and bFGF [35] which have been shown to activate their specific receptor tyrosine kinases, thereby initiating intracellular signaling to drive the angiogenic process.”
BackgroundHelm, C. E., Zisch, A., & Swartz, M. A. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21185 · Cited by 143
“In addition, when applied as an implanted fibrin matrix in vivo, this matrix-binding variant of VEGF121 produced patent capillary vessels as opposed to the leaky variety elicited by soluble VEGF121 in the same system (Ehrbar et al., 2004).”
BackgroundInfluentialInterleukin-6: An angiogenic target in solid tumours
Middleton, K., Jones, J. E., Lwin, Z., & Coward, J. I. G. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.004 · Cited by 150
“VEGF, a 45 kDa glycoprotein, was he first vascular-specific growth factor to be characterised nd is widely accepted to be the essential driver for vasculoenesis [23].”
BackgroundInfluentialRecent developments in the regulation of the angiogenic switch by cellular stress factors in tumors
North, S., Moenner, M., & Bikfalvi, A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.08.007 · Cited by 113
“[31] N.”
BackgroundA high-performance VEGF aptamer functionalized polypyrrole nanotube biosensor
Kwon, O. S., Park, S. J., & Jang, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.040 · Cited by 143
Antiangiogenic activity of Andrographis paniculata extract and andrographolide
Sheeja, K., Guruvayoorappan, C., & Kuttan, G. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.10.002 · Cited by 153
VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
Barratt, S. L., Flower, V., Pauling, J. D., & Millar, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051269 · Cited by 146
“VEGF-A receptors are abundantly expre both sides of the alveol r capillary membrane; alveolar epithelial type II (ATII) cells [25,28,29,5 , crophages [3,27], in the vascular bed [24,56,57] and by fibroblasts [52].”
BackgroundInfluentialDual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants
Peattie, R. A., Rieke, E. R., Hewett, E. M., Fisher, R. J., Shu, X. Z., & Prestwich, G. D. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.09.035 · Cited by 143
Murakami, M., Zheng, Y., Hirashima, M., Suda, T., Morita, Y., Ooehara, J., Ema, H., Fong, G.-H., & Shibuya, M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.150433 · Cited by 142
ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY
Quiroz–Mercado, H., Martinez-Castellanos, M. A., Hernández-Rojas, M. L., Salazar-Terán, N., & Chan, R. V. P. (2008) · Retina · doi:10.1097/iae.0b013e318159ec6b · Cited by 142
Liu, Y., Zhao, L., Li, D., Yin, Y., Zhang, C.-Y., Li, J., & Zhang, Y. (2013) · Protein & Cell · doi:10.1007/s13238-013-3092-z · Cited by 140
“VEGF is an angiogenic factor that can bind to receptors to induce endothelial cell migration and form new blood vessels (Ferrara et al., 2003).”
BackgroundAnti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues
Yang, Y., Zhang, Y., Cao, Z., Ji, H., Yang, X., Iwamoto, H., Wahlberg, E., Länne, T., Sun, B., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301331110 · Cited by 139
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.